Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit on June 24-26, 2025 in Boston, United States

Lipid-based nanoparticles are evolving-faster, safer and more precise than ever. With traditional LNPs struggling to reach tissues beyond the liver, the industry is doubling down on next generation technologies for extra-hepatic. In 2024 alone, Novo Nordisk invested $600M in NanoVation to push genetic medicines further, while Nanite and Saliogen joined forces to pioneer non-viral, lung-targeting nanoparticles.

Formerly known as the Next Gen Lipid-Based Nanoparticle Delivery Summit, the summit is the only industry-dedicated event laser-focused on extrahepatic targeting, delivery efficiency and scalable manufacturing for mRNA, siRNA, DNA and gene therapies.

Join 80+ delivery experts, CXOs and leading scientists from AstraZeneca, Novo Nordisk, Takeda, Orbital Therapeutics and more for three jam-packed days in Boston this June. Get exclusive insights, real-world case studies and cutting-edge strategies to supercharge your lipid-based delivery vehicles beyond the liver and into the next generation.

URLs:

Tickets: https://go.evvnt.com/2897583-2?pid=10008

Brochure: https://go.evvnt.com/2897583-3?pid=10008

Time: 8:00 AM - 4:30 PM

Prices:

Conference + Workshop Day - Pharma and Biotech Pricing: USD 4197.00,

Conference Only - Pharma and Biotech Pricing: USD 2999.00,

Conference + Workshop Day - Solution Provider Pricing: USD 5097.00,

Conference Only - Solution Provider Pricing: USD 3699.00,

Conference + Workshop Day - Academic and Research Pricing: USD 3597.00,

Conference Only - Academic and Research Pricing: USD 2599.00

Speakers: Bin Wu, Founder and Chief Executive Officer, Cytodigm, Gaurav Gulati, Senior Formulation Scientist, University of Cincinnati, Gilles Divita, CEO, Divincell, Kanika Suri, Scientist, Drug Product and Device Development, CMC, Takeda, Ketaki Deshmukh, Senior Scientist, Novo Nordisk, Mansoor Amiji, University Distinguished Professor, Northeastern University, Michael Grunwald, Senior Engineer, Non Viral Delivery, Orbital Therapeutics, Nahal Habibi, Senior Scientist, Non-Viral Delivery, Orbital Therapeutics, Nicholas P Restifo, Chief Medical Officer, Medici Therapeutics, Paula Hammond, Vice Provost for Faculty and Institute Professor, MIT, Pengbo Guo, Vice President, CybernaX Bio, Pierre Donnes, Vice President of Discovery, Strike Pharma, Qi-Ying Hu, Chief Executive Officer, Corti Therapeutics, Rebecca Haley, Senior Scientist, Script Biosciences, Shashi Murthy, Co-Founder and Chief Technology Officer, Nanite, Siddharth Patel, Director, Formulation and Delivery Science, Sail Biomedicines, Soultan Al-Halifa, Director, Biopharmaceutical Chemistry, Feldan Therapeutics, Umberto Capasso, Palmiero Senior Scientist, Novo Nordisk, Xiuying Li, Senior Scientist, Life Edit Therapeutics, Zimeng Wang, Associate Principal Scientist, AstraZeneca